Cancer-related interventional research must receive endorsement from the relevant Research Group(s), as mandated by the National Cancer Institute. The two-stage Protocol Review Monitoring System (PRMS) has been structured to support the full range of research embodied by the Cancer Consortium.

The first-stage Research Group review is documented in the Research Group Review Summary available at https://redcap.link/rgr. This form is completed by the Research Group(s) during their review of the protocol.

Key Contacts

PRMS@fredhutch.org for additional information or assistance with Research Group reviews

This first-stage review ensures Research Groups prioritize trials for their patient population and reduce the number of studies that are low-accruing due to competing trials.

Frequently Asked Questions

The Research Groups meet to evaluate their research portfolio and discuss the feasibility and merit of new studies. Consult the Admin contacts in each Research Group for assistance with scheduling reviews.

Submission to the SRC must take place within three months of the Research Group review to ensure timely and relevant reviews.

Additional information can be found in the Research Group Review Job Aid.

The Research Group review is documented in the Research Group Review Summary available at https://redcap.link/rgr

At the conclusion of the Research Group review, the Group Director or designee completes the form and returns the PDF copy to the investigator or study team. The completed form must be included in the submission for SRC review.

Research Group disapprovals must be reported at https://redcap.link/rgr or emailed to rejectedprotocols@fredhutch.org.

Each study requires one completed review form that indicates a primary group and collaborating groups (as appropriate). 

In most cases, the affiliation or membership of an investigator to a Research Group will be obvious (e.g., a breast cancer study will be reviewed by the Breast Oncology Group). 

If your study involves multiple Research Groups, consult with the Group Directors of the affiliated groups to decide which one should serve as the primary group.

Research Group Review must occur before submission for SRC review. These reviews are sequential and not concurrent. 

A new study submission will not be scheduled for SRC review until the completed Research Group Review Information Summary is submitted. This form is available at https://redcap.link/rgr. Once complete, a PDF copy of the form is attached to the REDCap email notification and must be included in the submission for SRC review.

Research Disease Groups

Breast Oncology

Gastrointestinal Oncology

Global Oncology

GU/Prostate Oncology

Hematologic Malignancies

Director: Ajay Gopal, MD, FACP

Director, Myeloid Malignancies:
Mary-Elizabeth Percival, MD

Director, Multiple Myeloma: 
Andrew Cowan, MD

Admin: 
uwhemeresearchstartup@fredhutch.org 
uwhemmalreg@fredhutch.org

Thoracic, Head, and Neck Oncology

Neurologic Oncology

Pediatric Oncology

Population Sciences

Research Modality Groups